NVO Novo Nordisk A/S
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 12-month channel falling
Price is between the lines.
- 12-month channel
- US$37.14 – US$41.83 · falling, −12% a year
- Price in channel
- 59% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$41.83
- Turns bearish below
- US$37.12
Price history, with the path projected 3 months forward
Updated 4:37 AM ET (79 h ago)
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$38.28
level as at 1 Nov 2026
Our target
US$41.34
by 17 Nov 2026
Projected move
8.0%
gross, before costs
Price is between our buy and target.
Target: NVO's usual move size (8.0%), the best return per day on this path.
This move size: reached in 40% of 21 past stretches, typically in 27 days. (0.30% per day)
- Upper line touches
- 2
- Lower line touches
- 3
- Fit confidence
- 63%
- Fitted
- 1 Nov 2026
Company information
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar
- Employees
- 68,794
- Country
- DK
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$174.58B
- Enterprise value
- —
- Beta
- 0.35
- Avg volume
- 12.16M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 35.12-64.16
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.